LID.L Share News (LID)

An independent medical study proving the cost-effectiveness of monitoring bloodflow during surgery has been welcomed by AIM-listed LiDCO, whose equipment was used for the trials.Published data examining the cost effectiveness of post-operative goal-directed therapy (GDT), a surgical intervention to monitor bloodflow to reduce the chances of patients suffering from oxygen debt, concluded that GDT adoption is both cost effective as well as clinically effective.LiDCO Chief Executive Terry O'Brien noted this was the first study to document the clinical and cost effectiveness of GDT in a post operative setting. "GDT adoption was cost effective and importantly for health care providers break even in a few months. Our product - the LiDCOplus monitor provides a very accurate continuous measurement of oxygen delivery, which is essential in determining the precise amount of oxygen being delivered to the patient's tissues."Shares in LiDCO were up 3.33% to 19.38p at 15:35 on Wednesday.OH